Pancreatic Ductal Adenocarcinoma
Mar 15, 2017
New biomarkers improve standard screening in Pancreatic Cancer
Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel, consisting of plasma tissue factor pathway inhibitor (TFPI) and tenascin-C (TNC-FN-III-C), as measured in plasma samples using an ELISA improves the prognostic value of CA 19-9. T...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
